Citations

Clear

1122 citation(s) found for "Hu, Dong".

The first-in-class SFK ‘OFF’ inhibitor NXP900 suppresses YAP signaling and demonstrates tumor growth suppression in cholangiocarcinoma
Kuipers, Hendrien , Carlson, Danielle Marie , Jessen, Erik , Abeynayake, Aushinie M , Sample, Jack W , Ozmert, Enis Hikmet , Mun, Dong-Gi , Tomlinson, Jennifer , Abdelrahman, Amro M , Werneburg, Nathan W , Li, B. , Cai, Meina , Conboy, Caitlin B , Borad, Mitesh J , Truty, Mark J , Pandey, Akhilesh , Ilyas, Sumera Irie , Gores, Gregory J. , Smoot, Rory L

Mayo Clinic

Clinical Cancer Research | November 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1158/1078-0432.ccr-26-0849 | PMID 43063487 Get It

Abstract Purpose: Cholangiocarcinoma (CCA) is an aggressive malignancy with limited targeted therapeutic options and few validated strategies for molecular patient stratification. Src family kinases (SFKs) and YAP signaling contribute to CCA progression, but prior approaches to therapeutically target this axis have shown limited efficacy. Here, we evaluate the preclinical therapeutic potential of NXP900, a first-in-class SFK ‘OFF’ inhibitor, in CCA. Experimental Design: The antitumor activity of NXP900 was assessed across CCA cell lines, syngeneic murine models, and patient-derived xenografts (PDXs). Mechanistic studies examined the impact of SFK ‘OFF’ inhibition on YAP signaling. Integrated transcriptomic and proteomic analyses were used to identify molecular features associated with response and resistance. Results: NXP900 demonstrated decreased tumor cell viability in CCA cell lines and significant tumor growth suppression in PDX models. SFK ‘OFF’ inhibition suppressed YAP signaling through dual mechanisms involving inhibition of YAP Y357 phosphorylation and activation of Hippo pathway signaling. NXP900 enhanced the efficacy of gemcitabine and cisplatin, supporting its potential use in combination regimens. Multiomic analyses identified enrichment of sensitivity to NXP900 in IDH-mutant CCA models, defining a clinically actionable molecular subset. In addition, resistance to SFK ‘OFF’ inhibition was associated with activation of an IL13RA2-AKT signaling axis, which was pharmacologically targetable, providing a rational framework for combination strategies. Conclusions: These findings establish SFK ‘OFF’ inhibition with NXP900 as a promising therapeutic strategy in CCA and support biomarker-guided clinical evaluation, including in molecularly defined patient subsets and in combination with standard chemotherapy.
Lysosomes as multifunctional hubs of CD8+ T cell regulation
Borges da Silva, Henrique , Dong, Haidong , Billadeau, Daniel D

Mayo Clinic

Journal of Cell Science | November 19, 2026 | Volume: 139 | Issue: 22 | Pages: No page available

10.1242/jcs.265033 | PMID 43055083 Get It

ABSTRACT Lysosomes have traditionally been recognized for their role in protein degradation. In CD8+ cytotoxic T lymphocytes (CTLs), most lysosomes represent a type of specialized lysosome-related organelle called a lytic granule (LG). LGs are comprised of lytic components, such as perforin (PRF1) and granzymes, that are required for the elimination of stressed, virus-infected or tumor cells. However, it is now well appreciated that lysosomes in CTLs have functions beyond cytotoxicity and serve as dynamic hubs for integrating signals driving cellular metabolism, mTORC1 signaling and autophagy. Together, this highly versatile organelle coordinates CTL activation, differentiation, memory formation and effector function. This Review examines the mechanisms by which lysosomes regulate LG biogenesis and secretion, autophagy, and metabolic reprogramming in CD8+ T cells. We additionally discuss how disruption of lysosomal pathways in CTLs impairs immune defense and contributes to immunodeficiency.
Latent effector capacity governs reversible T cell exhaustion: A theoretical mathematical model of PD-1 blockade response
Li, Ying , Dong, Haidong

Mayo Clinic

Science Advances | October 16, 2026 | Volume: 12 | Issue: 42 | Pages: No page available

10.1126/sciadv.aei0840 | PMID 42886782 Get It

T cell exhaustion is often viewed as a terminal state marked by irreversible loss of function during chronic infection and cancer. However, the rapid recovery of antitumor activity in clinical responders after PD-1 blockade suggests that some exhausted T cells retain hidden functional potential. To explain this paradox, we present a theoretical framework that separates latent effector capacity from active effector function. Latent effector capacity represents a history-dependent state reflecting preserved epigenetic accessibility and regulatory readiness, distinct from ongoing gene expression. In this model, PD-1 signaling acts as a reversible mask that suppresses effector function without eliminating the underlying effector capacity. The framework explains preserved chromatin accessibility, rapid reinvigoration after checkpoint blockade, and variable therapeutic responses. By incorporating nonlinear maintenance and erosion of latent effector capacity, the model predicts a bistable system with a point of no return beyond which exhaustion becomes irreversible. These principles may guide development of mechanistically informed biomarkers and artificial intelligence models predicting response to PD-1 therapy.
Combined Effect of Obstructive Sleep Apnea and Preserved Ratio Impaired Spirometry on Cardiovascular Outcomes
Chen, Lida , Dong, Yunzhou , Karim, Shahid , Wang, Jingjing , Ali, Isra H , Somers, Virend K.

Mayo Clinic

Journal of the American Heart Association | October 10, 2026 | Volume: 15 | Issue: 20 | Pages: No page available

10.1161/jaha.126.052921 | PMID 42857998 Get It

Background Obstructive sleep apnea (OSA)–chronic obstructive pulmonary disease overlap syndrome has been linked to worse cardiovascular outcomes. Preserved ratio impaired spirometry (PRISm) is recognized as an early stage of chronic obstructive pulmonary diseas. However, whether the coexistence of OSA and PRISm confers increased cardiovascular risk remains unknown. Methods Using data from the Sleep Heart Health Study, participants were categorized into 4 groups according to OSA and PRISm status. The primary outcome was major adverse cardiovascular and cerebrovascular events. The secondary outcome was cardiovascular disease mortality. Multivariable Cox regression models were used to evaluate the association of these groups with the risk of cardiovascular outcomes. Results During a median follow‐up of 11.45 years, the incidence of major adverse cardiovascular and cerebrovascular events was 17.00% in non‐OSA with normal lung function, 27.52% in non‐OSA with PRISm, 25.28% in OSA with normal lung function, and 49.40% in OSA with PRISm. After multivariable adjustment, compared with non‐OSA with normal lung function, the adjusted hazard ratios (HRs) for major adverse cardiovascular and cerebrovascular events were 1.20 (95% CI, 0.82–1.75) in non‐OSA with PRISm, 1.04 (95% CI, 0.89–1.21) in OSA with normal lung function, and 1.52 (95% CI, 1.08–2.12) in OSA with PRISm. Corresponding HRs for CVD mortality were 2.02 (95% CI, 1.26–3.24), 1.05 (95% CI, 0.81–1.35), and 2.17 (95% CI, 1.41–3.34), respectively. A significant sex interaction was observed ( P for interaction=0.009), with the association present only in women. Conclusions The coexistence of OSA and PRISm is independently associated with increased risk of adverse cardiovascular outcomes. This association is observed predominantly in women.
Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer
Zhou, Qin, Dibbs, Anna, Yin, Ping, Pavelko, Kevin D. , Dong, Haidong , Luo, Kuntian, Tu, Xinyi , Lucien, Fabrice , Park, Sean S. , Grams, Michael P. , Xu‐Welliver, Meng , Callaghan, Cameron , Lou, Zhenkun, Mutter, Robert W., Han, Yiqun , Zhu, Shouhai , Yin, Ping, Lou, Zhenkun , Mutter, Robert W. , Lucien-Matteoni, Fabrice

Mayo Clinic

Frontiers in Immunology | September 18, 2026 | Volume: 17 | Issue: No issue available | Pages: No page available

10.3389/fimmu.2026.1929236 | PMID 42827904 Get It

Introduction Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase involved in immune signaling and has been implicated in tumor-intrinsic resistance to DNA-damaging therapies. Although SYK activity has been associated with poor outcomes in triple-negative breast cancer (TNBC), its role in resistance to combined radiotherapy and immune checkpoint blockade remains unclear. Methods SYK expression and clinical relevance were assessed across multiple breast cancer cohorts, including radiotherapy-treated datasets. Integrated transcriptomic analyses were used to characterize SYK-associated immune states. The functional effects of pharmacologic SYK inhibition were evaluated using in vitro assays and an immunocompetent bilateral 4T1 tumor model in female BALB/c mice treated with radiotherapy and PD-1 blockade. Treatment-associated immune remodeling was assessed by flow cytometry and transcriptomic profiling. Results Across multiple cohorts, elevated SYK expression, particularly in TNBC, was associated with inferior clinical outcomes and immune dysregulation. Pharmacologic SYK inhibition enhanced tumor responses to radiotherapy and PD-1 blockade at both irradiated and distant tumor sites. These effects were accompanied by coordinated remodeling of the tumor immune microenvironment, including suppression of neutrophil-associated signatures and reductions in immunosuppressive myeloid populations, including M2-like macrophages and myeloid-derived suppressor cells. Discussion Pharmacologic SYK inhibition enhances responses to radiotherapy and PD-1 blockade in preclinical TNBC models and is accompanied by remodeling of the immunosuppressive myeloid compartment. These findings support further investigation of SYK-targeted strategies to improve responses to combined radiotherapy and immune checkpoint blockade.
Intracranial Targeting of Cholesterol Processing Reveals a Therapeutic Vulnerability that Reprograms Glioblastoma and Promotes Antitumor Immunity
Ulloa-Navas, María José , Whitehead, Rachel Melanie, Jones, Vanessa K. , Michaelides, Loizos , Brooks, Mieu, Basil, Aleeshba , Morales‐Gallel, Raquel , Gomez-Palmero, Cristina , Reynaga-Macias, Graciela Abril , Sánchez-Garavito, Jesús E. , Tapia-Dierking, Brianna, Nair, Asha, Llano, Juan Pablo Navarro Garcia de, Dryden, Ian, Rosenfeld, Steven S. , Ren, Yingxue , Quiñones‐Hinojosa, Alfredo , Sánchez-Garavito, Jesús E , Whitehead, Rachel, Llano, Juan Pablo Navarro Garcia de, Schiapparelli, Paula , Dryden, Ian, Clark, Victoria Elizabeth , Dong, Haidong , Deleyrolle, Loic P. , Qin, Hong , Herranz‐Pérez, Vicente , García‐Verdugo, José Manuel

Mayo Clinic

No container title available | August 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.18.745568 Get It

Abstract Glioblastoma (GBM) remains the most lethal primary brain cancer due to its remarkable metabolic plasticity and therapeutic resistance. Here, we identify cholesterol dependency as a therapeutically exploitable vulnerability in GBM using two FDA-approved drugs: the H1 histamine antagonist clemastine and the retinoid X receptor agonist bexarotene. Combined treatment induces potent synergistic anti-tumor activity across patient-derived glioma models, suppressing proliferation, stemness, and survival at sub-IC50 concentrations. Mechanistically, this therapy disrupts cholesterol biosynthesis, transport, and homeostasis, triggering endoplasmic reticulum stress and activation of the unfolded protein response, ultimately leading to autophagy and apoptotic cell death. Orthotopic patient-derived glioma models recapitulate these mechanisms in vivo, where local intracranial administration significantly reduces tumor progression and prolongs survival using fourfold lower doses than systemic intraperitoneal delivery. Single-cell RNA sequencing revealed activation of regeneration and plasticity programs, accompanied by immune microenvironment remodeling and enhanced inflammatory signaling. Importantly, syngeneic models preserved immune cell composition, supporting future integration with immunotherapeutic strategies. Together, these findings establish cholesterol dysregulation–induced metabolic collapse as a promising therapeutic approach for GBM.
From Routine Imaging to Risk Stratification: Multimodal Vision–Language Survival Modeling for Pancreatic Cancer
Le, David , Medero, Ramon Luis Correa, Tariq, Amara, Joshi, Vedant, Zhang, Zhemin , Murlidhar, Fnu, Dong, Hexin, Peng, Yifan, Shih, George, Wang, Zhen, Pannala, Rahul , Yano, Motoyo , Banerjee, Imon, Correa, Ramón , Tariq, Amara , Dong, Hexin, Peng, Yifan , Shih, George , Banerjee, Imon

Mayo Clinic

2026 IEEE 14th International Conference on Healthcare Informatics (ICHI) | August 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 515-524

10.1109/ichi69079.2026.00071 | PMID 42631298 Get It

Humanizing care in the ICU: how system pressures shape interacting patterns of hurry, blur, burden, and cruelty
Zahidy, Misk Al, Claros, Ana Gabriela, Mulanovich, Katerina, Lizarazo, Maria Jose , Chavez, Maria Mateo, Ahmed, Ahmed Sayed, Dong, Yue, Gajic, Ognjen, Ahmad, Sumera, Al Zahidy, Misk, Gionfriddo, Michael R. , Mateo Chavez, Maria, Sayed Ahmed, Ahmed , Mahmoud, Mohamed A., Chavez, Maria Mateo , Gajic, Ognjen , Montori, Víctor M.

Mayo Clinic

Frontiers in Health Services | August 11, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/frhs.2026.1867800 | PMID 42643350 Get It

Background Intensive care units are high-acuity environments characterized by time pressure, medical complexity, and organizational demands. These conditions may influence clinicians’ ability to provide patient-centered care and contribute to forms of care perceived as fragmented or dehumanizing. Objective To examine how ICU clinicians describe and make sense of the pressures shaping everyday critical care practice, and how these pressures give rise to interacting patterns of care, including those described as hurry, blur, burden, and cruelty. Methods We conducted a qualitative study using focus groups with ICU clinicians from a large academic health system. Discussions were informed by the concept of the pathologies of care as sensitizing concepts. Four focus groups were held with physicians, nurses, advanced practice nurses, and a social worker ( N = 14). Transcripts were analyzed using directed content analysis with both deductive and inductive coding. Results Clinicians described these patterns not as discrete phenomena but as interrelated, context-dependent processes shaped by shared operational pressures such as time constraints, workload, and information demands. These dynamics were often viewed as inherent to the structure and culture of ICU care and were described as co-occurring and compounding. Communication emerged as both a contributor to and a potential mechanism for mitigation, alongside system-level strategies such as reducing documentation burden and leveraging artificial intelligence to support care delivery. Conclusions Patterns reflected in hurry, blur, burden, and cruelty are best understood as emergent properties of complex care systems. Addressing these dynamics may require system-level approaches to improve communication, reduce workload pressures, and support more patient-centered, humanizing care.
Cellular senescence is associated with age-related loss of liver zonation and hepatocyte function
Laux, L , Aristel, Alisha, Ali, Syed, Evensen, K. Garrett , Havas, Aaron , Miao, Zhen , Zhang, Jane, Peters, Samuel, Hu, Jiayi , Angelini, Luise, Klaers, Maggie, Brocksome, Jennie, Lewis, Adam , Paidimukkala, N., Brown, Mary E., Carver, Chase M., Albrecht, Jeffrey H. , Wehner, April , Adams, Peter, Aliferis, Constantin, Adeyi, Oyedele, Dong, Xiao, Wang, Jinhua, Zhang, Nancy, Adeyi, Oyedele , Adeyi, Oyedele , Lande, Kathryn , Li, Meiyi , Havas, Aaron , Zhang, Jane, Peters, Sam , Angelini, Luise, Brown, Mary E., Carver, Chase Matthew , Schafer, Marissa , Khosla, Sundeep , Wang, Jinhua , Robbins, Paul D. , Niedernhofer, Laura J. , Miao, Zhen , Khosla, Sundeep , Niedernhofer, Laura J

Mayo Clinic

No container title available | August 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.08.743614 | PMID 42845483 Get It

Abstract The liver is organized into tightly regulated zones with distinct metabolic functions but zonation erodes with age. Cellular senescence contributes to aging and liver diseases, however, its impact on aging biology is ill-defined. As part of The Cellular Senescence Network Consortium, we used multiple spatial transcriptomics approaches (GeoMx, Visium, CosMx) with snRNA-seq to profile senescence signatures, zonation markers, and metabolic pathways in livers from wild-type (WT) mice of multiple ages. We observed a loss of canonical zone signatures in aged mouse livers characterized by “expansion” of midlobular (zone 2) marker gene expression, accompanied by diminished expression of zone 3 marker genes by middle-age (18 months), indicative of loss of cell identity. Multiple analytic approaches identified distinct age-, zone- and sex-specific senescence signatures, which were significantly associated with zonation markers changes. This was recapitulated in Ercc1 mutant models of accelerated senescence, supporting a causal role of senescent cells in liver aging. A “no-zone” hepatocyte-like cluster expanded with age and with the strongest Senescence-Associated Secretory Phenotype (SASP) profile. Gene expression profiles from senescent hepatocytes implicate decreased WNT signaling and increased BMP as contributing to age-related loss of zonation. Together, these data elucidate the role of senescent cells in driving aging biology in non-diseased liver through disruption of cell:cell signaling and the loss of metabolic and cell identity gene expression necessary for hepatocyte function.
nnMobileNet++: Towards Efficient Hybrid Networks for Retinal Image Analysis
Li, Xin , Zhu, Wenhui , Dong, Xuanzhao , Xiong, Yujian, Dumitrașcu, Oana , Wang, Hao , Wang, Yalin

Mayo Clinic

2026 IEEE/CVF Winter Conference on Applications of Computer Vision Workshops (WACVW) | August 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: 282-292

10.1109/wacvw68408.2026.00034 Get It